Ligand Pharms Inc Cvr
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more
Ligand Pharms Inc Cvr (LGNDZ) - Total Assets
Latest total assets as of June 2025: $1.48 Billion USD
Based on the latest financial reports, Ligand Pharms Inc Cvr (LGNDZ) holds total assets worth $1.48 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ligand Pharms Inc Cvr - Total Assets Trend (1994–2024)
This chart illustrates how Ligand Pharms Inc Cvr’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ligand Pharms Inc Cvr - Asset Composition Analysis
Current Asset Composition (December 2024)
Ligand Pharms Inc Cvr's total assets of $1.48 Billion consist of 35.2% current assets and 64.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.7% |
| Accounts Receivable | $38.38 Million | 4.1% |
| Inventory | $14.11 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $266.65 Million | 28.3% |
| Goodwill | $105.25 Million | 11.2% |
Asset Composition Trend (1994–2024)
This chart illustrates how Ligand Pharms Inc Cvr's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ligand Pharms Inc Cvr's current assets represent 35.2% of total assets in 2024, a decrease from 89.1% in 1994.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2024, down from 16.3% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is intangible assets at 28.3% of total assets.
Ligand Pharms Inc Cvr Competitors by Total Assets
Key competitors of Ligand Pharms Inc Cvr based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Ligand Pharms Inc Cvr - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ligand Pharms Inc Cvr generates 0.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Ligand Pharms Inc Cvr generates $ 0.96 in net profit.
Ligand Pharms Inc Cvr - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.69 | 16.82 | 20.28 |
| Quick Ratio | 24.30 | 15.70 | 19.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $723.38 Million | $ 293.69 Million | $ 815.44 Million |
Ligand Pharms Inc Cvr - Advanced Valuation Insights
This section examines the relationship between Ligand Pharms Inc Cvr's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 19.6% |
| Total Assets | $941.77 Million |
| Market Capitalization | $57.77K USD |
Valuation Analysis
Below Book Valuation: The market values Ligand Pharms Inc Cvr's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Ligand Pharms Inc Cvr's assets grew by 19.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ligand Pharms Inc Cvr (1994–2024)
The table below shows the annual total assets of Ligand Pharms Inc Cvr from 1994 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $941.77 Million | +19.63% |
| 2023-12-31 | $787.22 Million | +3.22% |
| 2022-12-31 | $762.67 Million | -41.22% |
| 2021-12-31 | $1.30 Billion | -4.75% |
| 2020-12-31 | $1.36 Billion | -8.87% |
| 2019-12-31 | $1.49 Billion | +13.87% |
| 2018-12-31 | $1.31 Billion | +81.66% |
| 2017-12-31 | $722.65 Million | +20.12% |
| 2016-12-31 | $601.59 Million | +19.58% |
| 2015-12-31 | $503.06 Million | +94.96% |
| 2014-12-31 | $258.03 Million | +146.42% |
| 2013-12-31 | $104.71 Million | +0.43% |
| 2012-12-31 | $104.26 Million | -14.79% |
| 2011-12-31 | $122.35 Million | +61.93% |
| 2010-12-31 | $75.56 Million | -46.72% |
| 2009-12-31 | $141.81 Million | -17.29% |
| 2008-12-31 | $171.45 Million | -1.06% |
| 2007-12-31 | $173.28 Million | -46.86% |
| 2006-12-31 | $326.05 Million | +109.75% |
| 2005-12-31 | $155.45 Million | -41.61% |
| 2003-12-31 | $266.23 Million | -1719.03% |
| 2002-12-31 | $-16.44 Million | -114.00% |
| 2001-12-31 | $117.47 Million | +3.57% |
| 2000-12-31 | $113.42 Million | -15.73% |
| 1999-12-31 | $134.60 Million | -13.72% |
| 1998-12-31 | $156.00 Million | +45.25% |
| 1997-12-31 | $107.40 Million | +5.19% |
| 1996-12-31 | $102.10 Million | +9.08% |
| 1995-12-31 | $93.60 Million | +100.43% |
| 1994-12-31 | $46.70 Million | -- |